KYTXKyverna Therapeutics, Inc.
What is the market doing?
In a downtrend (−26% vs 200-day). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 27). Price is −26% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How KYTX is trading
Kyverna Therapeutics, Inc. is +14% over the past year while the S&P 500 is +18%: 4.0 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −26%
vs 200-day average · a clear downtrend
- RSI (14)
- 27
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 45%
Below its 52-week high
Details›
- Last close2026-10-08
- $6.18
- 1 monthS&P 500 +1.6%
- −19%
- 1 yearS&P 500 +18%
- +14%
- vs 50-day average$7.61
- −19%
- 52-week high
- $11.25
- 52-week low
- $6.15
- Annualised volatility
- 96%
| Year | Return |
|---|---|
| 2026 (year to date) | −34% |
| 2025 | +151% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −14% |
| Feb | 2 | 1 of 2 | −4.9% |
| Mar | 3 | 1 of 3 | −12% |
| Apr | 3 | 2 of 3 | −5.8% |
| May | 3 | 1 of 3 | −3.3% |
| Jun | 3 | 2 of 3 | −5.0% |
| Jul | 3 | 2 of 3 | +4.5% |
| Aug | 3 | 2 of 3 | +4.2% |
| Sep | 3 | 1 of 3 | +1.0% |
| Oct | 3 | 1 of 3 | +1.5% |
| Nov | 2 | 2 of 2 | +15% |
| Dec | 2 | 1 of 2 | −6.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry